Jazz Pharmaceuticals plc
JAZZHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeJazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. Valued at $15.53B, JAZZ is a large-cap name in its sector. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Market Cap
$15.53B
Beta
0.32
P/E (TTM)
2062.75
P/E (Fwd)
9.60
EPS (TTM)
$0.12
EPS (Fwd)
$25.78
ROE
0.7%
ROA
6.9%
Cash
$2.87B
Total Debt
$5.42B
Free CF
$1.34B
52W Change
119.3%
Annual Financials
Cash vs Debt
On the balance sheet, JAZZ has $2.87B in cash with $5.42B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $1.34B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 0.7% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $3.66B to $4.27B.
The relatively low beta of 0.32 suggests JAZZ is a less volatile holding compared to the broader index. At over 50x earnings, JAZZ carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing JAZZ.